This article first appeared on Insights Association Website.

Sometimes, it’s the little things that have the biggest impact.

A few years ago, I was on a screening call with one of our regular panelists, a pharmacy director, and soon sensed something was wrong. His replies were brisk and his voice sounded tight. When I asked how he was doing, the story spilled out: he was developing a new service for long-term care facilities and between that project and demands on his professional and personal time, he was totally stressed out.

This article first appeared on Insights Association Website.

As Director of Client Services for MedSurvey, a medical market research company, I'm not generally in the habit of publicizing scathing online reviews of my own company. In fact, I think it’s fair to say that as a general rule, circulating a review that states “MedSurvey IS A SCAM” is not sound business practice. And yet here I am, announcing to the world, “One of our survey respondents filed a one-star review with the Better Business Bureau accusing us of being a scam.” And yes, a review like this is alarming to us at MedSurvey. But to our fellow sample companies and clients, I cannot emphasize enough: This review should be alarming to all of us.

This article first appeared on Insights Association Website.

I regularly speak with prospective and current clients about their decision-making process for choosing a vendor for their projects. Often, they make decisions based on numbers that look good on paper, only to find that these numbers do not accurately predict the success of their projects. I’ve come to understand that for many clients, selecting a vendor can sometimes feel like rolling the dice.

Physician respondents are not a limitless resource

This cover story first appeared in the Quirks Special Healthcare Issue (January/February 2020).

Building a health care-focused data collection company over the past two decades has been an interesting, rewarding and oftentimes frustrating process for me. The challenge of executing research with geographic constraints of an earlier era has been replaced by more recent concerns of adequate sample supply, vendor transparency and the quality of respondents and data.

This article first appeared on Insights Association Website.

Over the course of my 15-plus year tenure at MedSurvey, a data collection company for healthcare and life science market research, I have worn many hats. Because I joined the company early on, when it was still quite small, I had the opportunity to become closely involved in nearly every aspect of the business, from finance to project management to business development—and just about everything in between. Now, simply by virtue of having been part of a fast-growing company for so many years, I can confidently say (without bragging, of course) that I have gone from “the IT expert” to “the expert on everything.” My colleagues joke that whenever a tricky question comes up, regardless of the business area, the answer is always “Ask Gen.” And there is one especially complex question from our business development team that comes up again and again. Because the question highlights just how vital transparency is to the market research process, I believe it is crucial that we address it not only within our own company but with our industry as a whole.

An Apology for the Lack of Transparency in the MR Sample Process

This article first appeared on Insights Association Website.

When I first came to MedSurvey four years ago as Vice President of Business Development (and the first and only salesperson in the company’s history), I was a complete newcomer to the market research industry. Previously, I had worked in sales for major companies and logos, selling media and advertising solutions on a national scale and managing multi-million-dollar budgets. But with respect to market research, I was an outsider with very little knowledge of the industry. As a result, for the first six months of my new career at MedSurvey, I set out to learn everything I could about the industry, to understand how and why clients worked with us, to uncover the gaps, and to get a good understanding from clients about their needs and expectations. What I found not only surprised me—it baffled me.

This article first appeared in Quirks June/July 2019 issue

Over the past 15 years, the medical market research landscape has undergone dramatic changes. As the health care field has advanced and doctors have become more specialized, pharmaceutical companies have begun to seek survey respondents who are more specialized as well. A decade ago, a typical research project might target a list of 100 oncologists, broadly defined; today, projects may target 100 oncologists who specialize in a very specific condition, work with a very specific set of devices and are affiliated with a very specific subset of medical institutions at the forefront of their fields.

As medical market researchers, we are tasked with providing crucial data to pharmaceutical companies. They are counting on us to deliver accurate research results that will have a critical impact on future business and marketing decisions, trickling all the way down to how medications are prescribed and patients are treated.

Yet many medical market research companies tend to overlook one simple issue, resulting in erroneous data that can lead to costly, even multi-million-dollar mistakes.

My biggest takeaway after three months at a market research sample partner

Over the past 12 years, I have worked for various market research companies, and in that time, I’ve held many roles and seen the space from multiple different perspectives. I knew the ins and outs of the industry, and to be honest, I thought I had seen it all. So I was taken by surprise when I came to MedSurvey and was introduced to an entirely new approach.

First a little context - I am a cardiothoracic anesthesiologist working at a hospital in Philadelphia. Recently, I reconnected and was having dinner with a childhood friend, who happened to have founded a medical market research company many years ago (full disclaimer, the friend is Paul Golota, co-founder and executive vice president of MedSurvey). When we started discussing his line of work, he asked me if I have ever participated in paid medical market research surveys. My answer was “yes, but I rarely do it anymore.” After discussing my string of bad experiences with survey companies, he asked me if I would consider authoring a blog post about my hesitation to participate and possibly outline a few suggestions that would make participating more appealing. This is an attempt to do just that and give the market research industry a physician’s perspective on participating in paid medical surveys.